Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

GE’s USD 1 billion Biotech Acquisitions from Thermo Fisher to Boost Discovery of New Drugs and Diagnostic Products

By Doris Mendieta
Posted on 02 Feb 2014
Image: Thermo Fisher Scientific\'s HyClone line of cell culture media and sera will be integrated into GE Healthcare\'s life science division (Photo courtesy of Thermo Fisher Scientific).
Image: Thermo Fisher Scientific\'s HyClone line of cell culture media and sera will be integrated into GE Healthcare\'s life science division (Photo courtesy of Thermo Fisher Scientific).
GE Healthcare (Chalfont St. Giles, United Kingdom) is set to purchase Thermo Fisher Scientific's (Milford, MA, USA) HyClone line of cell culture media and sera, as well as Thermo Fisher's gene modulation and magnetic beads businesses. Cost of the transaction is estimated at approximately 1.06 billion USD.

Thermo Fisher’s well respected HyClone cell culture media and sera products will complement GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, which will enable GE Healthcare to offer its customers a substantially wider range of technologies and services.

John Dineen, president and CEO of GE Healthcare said, “Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost.”

Kieran Murphy, president and CEO of GE Healthcare’s life sciences division said, “We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business. In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”

Related Links:

GE Healthcare 
Thermo Fisher Scientific



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.